Key Takeaways
- Volume-led 37% revenue surge: Nine-month revenue grew 37% driven by 15% volume growth, mostly from the Derivatives business, as new projects came online and the revenue mix diversified.
- Margins and returns both jumped: EBITDA margin reached 28% (vs 26% a year ago) and ROCE hit 25%, while net debt-to-EBITDA improved sharply from 2x to 0.8x after INR 380 crores of debt repayment.
- Two new expansions announced: CPVC resin capacity will double to 150,000 TPA and Epichlorohydrin will double to 100,000 TPA, both targeting commissioning in H1 FY27.
- Chlorotoluene is the near-term catalyst: The multi-product value chain project is in final commissioning and will start contributing from Q4 FY25, with full impact expected from FY27.
- What to watch next quarter: The pace of Chlorotoluene ramp-up, ECU realization stability around INR 31,000, and any demand signal from the CPVC and ECH markets that would validate the newly announced capacity doubles.
Volume & Margin Performance
- Volume engine running hot: 15% volume growth over nine months came predominantly from the Derivatives segment, aided by recently commissioned projects and a diversified revenue model.
- Derivatives capacity mix shift: Derivatives capacity utilization was stagnant or slightly lower versus Q2, so chlor-alkali's contribution to the total mix rose to roughly 50% for the quarter.
- Margin stability across segments: Both Chlor-alkali and Derivatives segments held margins around 25%, with only marginal price changes in Derivatives (some products down 3 to 4%, some up 3 to 4%).
- Other expenses rose on production-linked costs: Other expenses increased from INR 56 crores to INR 70 crores, attributed to direct production costs (water, overall operations) and higher logistics expenses.
- Interest cost collapsed on debt paydown: Interest cost became negligible in Q3 because the company made a substantial debt repayment and booked a positive mark-to-market effect from derivative contracts.
ECU & Realization Dynamics
- ECU improved on caustic strength: Caustic soda realizations improved to roughly INR 43,000 per tonne while chlorine remained negative at roughly INR 9,000, yielding an ECU of INR 31,000 to 32,000.
- Negative chlorine is factored into ECU, not expenses: Management clarified that the negative chlorine carry is embedded in ECU realization and does not inflate other expenses.
- ECU range expected to hold: Management expects ECU to remain in the same INR 31,000 range in the coming months.
- Coal and salt costs were not flat: Coal and salt prices moved quarter-on-quarter, though no quantification was provided.
Chlorotoluene: The Immediate Catalyst
- Commissioning is underway now: The Chlorotoluene value chain project is in its final Capex phase, with phased commissioning already in progress and full completion expected by February or March.
- A 10-to-11-product ramp: The project spans 10 to 11 different products; trials are ongoing and will accelerate through Q4 and into Q1 FY26.
- Optimum utilization by end of FY26: Management expects to reach optimum operating levels by the end of FY26, with full-year impact visible from FY27.
Maulik Patel: "So, yes, not 2 and 2.5 years. I would say to the optimum level, I think we will reach by end of FY '26 only."
CPVC & Epichlorohydrin: The FY27 Growth Wave
- Two capacity doubles announced: CPVC resin will expand from 75,000 TPA to 150,000 TPA and Epichlorohydrin from 50,000 TPA to 100,000 TPA, both within the existing complex where space is already allocated.
- Commissioning timeline is H1 FY27: Both projects are expected to commission in the first half of FY27 and begin contributing from that year onward.
- CPVC ramp-up to optimum by end of FY27 or early FY28: Management expects to reach optimum utilization faster than the original facility, citing two years of customer-approval experience, with full-year benefit visible in FY28.
- ECH pricing tailwind expected: Raw material prices are rising globally and logistics costs are increasing, so Epichlorohydrin prices are expected to move up going forward.
- PVC antidumping supports CPVC resin pricing: With antidumping duty and BIS measures coming for PVC, international and domestic PVC prices will rise, and the company expects to pass this through to CPVC resin customers.
- CPVC margin sustainability targeted at 25%: Management expects to continue CPVC margins around 25% in the coming period.
- ECH market absorption path: India's ECH capacity was 80,000 tonnes; another large player is entering the epoxy resin market, taking it to nearly 150,000 tonnes, and management believes the Indian market will absorb the quantity over the long term while exports to Europe continue.
Milind Kotecha: "Barring few quarters, it can be that it is subdued. But otherwise, on a longer horizon, over a 5-year period, we expect the CPVC demand to reach around 5 lakh tonnes by FY 2029 or FY 2030."
Demand Environment & Strategy
- Slow but improving demand: The overall chemical industry has witnessed improvement, but the pace of demand growth remains slow; management expects continuous improvement.
- Domestic demand outpaces global: The domestic demand scenario is better than the global market scenario.
- Diversification is the stated strategy: Management is executing a plan of expansion and diversification into a multiproduct portfolio serving various industries, targeting consistent growth.
- Hydrogen peroxide special grades deferred: The company can make food-grade and other special grades but will not set up that capability until the market is large enough to justify the volume.
Maulik Patel: "Currently, we are not making those grades right now. We know how to make those grades, we can make those grades, but currently, we are not interested because of the volume."
Financial Position & Cost Outlook
- ROCE jumped to 25%: ROCE (including CWIP) improved from 18% to 25%, driven by better volume growth from an optimum revenue mix and growth in absolute EBIT.
- Debt reduction accelerated: Net debt-to-EBITDA improved from 2x to 0.8x, with INR 380 crores repaid over nine months.
- Finance cost to normalize in Q4: After a negligible Q3, finance cost is expected to return to roughly INR 14 to 15 crores in Q4.
- Segment margin breakdown not disclosed: Management declined to share product-wise gross and EBITDA margins for Caustic Soda versus Derivatives, and did not have a raw material cost split between the two segments on hand.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Chlorotoluene commissioning | Project fully commissioned | By March (Q4 FY25) |
| Chlorotoluene optimum utilization | Reach optimum operating levels | End of FY26 |
| CPVC and ECH expansion commissioning | Both projects commissioned | H1 FY27 |
| CPVC new capacity optimum utilization | Reach optimum level on 75,000 TPA addition | End of FY27 / beginning of FY28 |
| ECU realization range | Remain around INR 31,000 | Coming months |
| Finance cost normalization | Return to INR 14–15 crores per quarter | Q4 FY25 |
| CPVC margin sustainability | Maintain margins around 25% | Coming period |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹649 cr, +37% YoY |
| EBITDA | ₹183 cr, +49% YoY |
| EBITDA margin | 28%, vs 26% in Q3 FY24 |
| PAT | ₹104 cr, +110% YoY |
| PAT margin | 16%, vs 10% in Q2 FY24 |
| Sales volume growth | 11% YoY, 1% QoQ |
| Capacity utilization | 81%, similar to Q3 FY24 |
| ROCE (trailing 12 months, including CWIP) | 25%, vs 18% as on 31 Dec 2024 |
| ROCE (excluding CWIP) | 31% |
| Net debt to EBITDA | 0.8x, vs 2x at end of Dec 2023 |
| Debt repaid in 9 months ended 31 Dec 2024 | ₹380 cr |
| Derivatives revenue contribution (9M FY25) | 54%, vs 44% in 9M FY24 |
| Caustic soda capacity utilization | ~80% |
| ECU realization | ~₹31,000–32,000 |
| CPVC capacity utilization | 50–55% |
| ECH capacity utilization | 80–85% |
| Interest cost | Negligible, due to debt repayment and positive FOREX derivative impact |